LOW-GRADE SEROUS OVARIAN CANCER
Clinical trials for LOW-GRADE SEROUS OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new LOW-GRADE SEROUS OVARIAN CANCER trials appear
Sign up with your email to follow new studies for LOW-GRADE SEROUS OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody combo shows promise for tough ovarian cancers
Disease control Recruiting nowThis study tests an experimental drug called ubamatamab, given alone or with another drug (cemiplimab), for people with ovarian cancer or other cancers that have come back. The goal is to find safe doses and see if the drugs can shrink tumors. About 890 adults with recurrent ovar…
Matched conditions: LOW-GRADE SEROUS OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New drug combo aims to slow a rare ovarian cancer
Disease control Recruiting nowThis study tests whether a combination of two drugs, avutometinib and defactinib, works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer has returned after platinum-based therapy will be randomly assign…
Matched conditions: LOW-GRADE SEROUS OVARIAN CANCER
Phase: PHASE3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC